Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Ocular Therapeutix Inc’s stock clocked out at $12.56, down -1.18% from its previous closing price of $12.71. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 1.14 million shares were traded. OCUL stock price reached its highest trading level at $12.75 during the session, while it also had its lowest trading level at $12.48.
Ratios:
To gain a deeper understanding of OCUL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.78 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21. On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 24 ’25 when Nayak Sanjay sold 1,878 shares for $12.04 per share. The transaction valued at 22,611 led to the insider holds 277,860 shares of the business.
Dugel Pravin sold 19,530 shares of OCUL for $235,141 on Nov 24 ’25. The insider now owns 3,157,960 shares after completing the transaction at $12.04 per share. On Nov 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,007 shares for $12.02 each. As a result, the insider received 36,144 and left with 191,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2675876352 and an Enterprise Value of 2408112128. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.97 while its Price-to-Book (P/B) ratio in mrq is 8.51. Its current Enterprise Value per Revenue stands at 43.169 whereas that against EBITDA is -9.265.
Stock Price History:
The Beta on a monthly basis for OCUL is 0.93, which has changed by 0.50419164 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $16.44, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 2.27%, while the 200-Day Moving Average is calculated to be 20.17%.
Shares Statistics:
It appears that OCUL traded 3.31M shares on average per day over the past three months and 3181270 shares per day over the past ten days. A total of 213.05M shares are outstanding, with a floating share count of 186.91M. Insiders hold about 12.27% of the company’s shares, while institutions hold 79.00% stake in the company. Shares short for OCUL as of 1765756800 were 10593646 with a Short Ratio of 3.20, compared to 1763078400 on 13173573. Therefore, it implies a Short% of Shares Outstanding of 10593646 and a Short% of Float of 4.99.
Earnings Estimates
Ocular Therapeutix Inc (OCUL) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.34 and -$1.49 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$1.48, with 3.0 analysts recommending between -$1.3 and -$1.58.
Revenue Estimates
In. The current quarter, 12 analysts expect revenue to total $16.14M. It ranges from a high estimate of $28.4M to a low estimate of $11.6M. As of. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $17.08MFor the next quarter, 12 analysts are estimating revenue of $14.01M. There is a high estimate of $16.6M for the next quarter, whereas the lowest estimate is $11.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.1M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.83M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $66.04M in the next fiscal year. The high estimate is $115.2M and the low estimate is $52.3M.
